Knee Injections for Obese Patients with Knee Arthritis

Last updated: January 29, 2025
Sponsor: Mayo Clinic
Overall Status: Active - Recruiting

Phase

4

Condition

Joint Injuries

Osteoarthritis

Treatment

Triamcinolone Acetonide Standard Dose

Triamcinolone Acetonide Low Dose

Clinical Study ID

NCT06782529
24-005200
  • Ages 55-85
  • All Genders

Study Summary

The purpose of this study is to assess obese patients with knee arthritis and determine the non-inferiority of a low dose steroid treatment vs. standard dose steroid treatment for two knee outcome measures: pain and function.

Eligibility Criteria

Inclusion

Inclusion Criteria:

• Patients with BMI ≥30 kg/m2 and radiograph-proven knee osteoarthritis who are interested in receiving a steroid injection for knee arthritis.

Exclusion

Exclusion Criteria:

  • BMI < 30 kg/m2

  • Uncontrolled diabetics with a hemoglobin A1c > 8%

  • No other treatment within the time frame of the study.

  • Patients that are undergoing physical therapy at the time of the study.

Study Design

Total Participants: 40
Treatment Group(s): 2
Primary Treatment: Triamcinolone Acetonide Standard Dose
Phase: 4
Study Start date:
January 24, 2025
Estimated Completion Date:
March 24, 2026

Connect with a study center

  • Mayo Clinic in Florida

    Jacksonville, Florida 32224
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.